Wells Fargo & Company Revance Therapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 38,698 shares of RVNC stock, worth $99,453. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,698

Previous 62,930 38.51%

Holding current value

$99,453

Previous $161,000 38.51%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$2.57 - $2.57 $62,276 - $62,276	-24,232 Reduced 38.51%	38,698 $99,000
Q2 2024 Aug 13, 2024	BUY	$2.34 - $4.73 $18,385 - $37,163	7,857 Added 14.27%	62,930 $161,000
Q1 2024 May 10, 2024	BUY	$4.65 - $9.31 $78,092 - $156,352	16,794 Added 43.87%	55,073 $270,000
Q4 2023 Feb 09, 2024	BUY	$5.81 - $11.2 $17,116 - $32,995	2,946 Added 8.34%	38,279 $336,000
Q3 2023 Nov 13, 2023	SELL	$11.47 - $25.07 $420,650 - $919,417	-36,674 Reduced 50.93%	35,333 $405,000
Q2 2023 Aug 15, 2023	BUY	$24.7 - $37.61 $444,353 - $676,603	17,990 Added 33.3%	72,007 $1.82 Million
Q1 2023 May 12, 2023	SELL	$18.36 - $35.27 $554,839 - $1.07 Million	-30,220 Reduced 35.87%	54,017 $1.74 Million
Q4 2022 Feb 13, 2023	SELL	$18.32 - $30.66 $151,469 - $253,496	-8,268 Reduced 8.94%	84,237 $1.56 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $2,407 - $4,782	168 Added 0.18%	92,505 $2.5 Million
Q2 2022 Aug 12, 2022	SELL	$11.52 - $20.4 $127,791 - $226,297	-11,093 Reduced 10.73%	92,337 $1.28 Million
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $825,759 - $1.36 Million	-66,809 Reduced 39.24%	103,430 $2.02 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $4.03 Million - $9.01 Million	-323,145 Reduced 65.5%	170,239 $2.78 Million
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $2.23 Million - $2.87 Million	86,375 Added 21.22%	493,384 $13.7 Million
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $358,396 - $425,796	-13,373 Reduced 3.18%	407,009 $12.1 Million
Q1 2021 May 13, 2021	SELL	$24.03 - $29.97 $226,314 - $282,257	-9,418 Reduced 2.19%	420,382 $11.8 Million
Q4 2020 Feb 09, 2021	BUY	$23.41 - $28.34 $4.16 Million - $5.04 Million	177,807 Added 70.56%	429,800 $12.2 Million
Q3 2020 Nov 05, 2020	BUY	$23.23 - $34.3 $4.05 Million - $5.98 Million	174,266 Added 224.2%	251,993 $6.34 Million
Q2 2020 Aug 13, 2020	BUY	$12.6 - $26.55 $266,502 - $561,559	21,151 Added 37.39%	77,727 $1.9 Million
Q1 2020 May 14, 2020	BUY	$12.46 - $27.81 $704,936 - $1.57 Million	56,576 New	56,576 $837,000

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Revance Therapeutics, Inc. Transaction History